Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands |
3 Months Ended | 9 Months Ended | ||||
|---|---|---|---|---|---|---|
Sep. 30, 2026 |
Sep. 30, 2025 |
Sep. 30, 2026 |
Sep. 30, 2025 |
|||
| Revenue: | ||||||
| Total revenue | $ 56 | $ 15 | $ 161 | $ 123 | ||
| Operating expenses: | ||||||
| Cost of revenue | 16 | 0 | 52 | 20 | ||
| Research and development | 4,447 | 3,513 | 8,247 | 8,508 | ||
| General and administrative | 1,940 | 2,150 | 5,617 | 7,183 | ||
| Total operating expenses | 6,403 | 5,663 | 13,916 | 15,711 | ||
| Loss from operations | (6,347) | (5,648) | (13,755) | (15,588) | ||
| Other income (expense), net: | ||||||
| Interest income | 50 | 40 | 152 | 183 | ||
| Interest expense | (665) | (649) | (2,151) | (1,936) | ||
| Issuance costs for common stock warrant liabilities | 0 | 0 | (393) | 0 | ||
| Loss on initial issuance of equity | 0 | 0 | (4,582) | 0 | ||
| Change in fair value of common stock warrant liabilities | 7,493 | (1,728) | 2,301 | 267 | ||
| Change in fair value of derivative liabilities | 3,368 | (797) | 748 | (89) | ||
| Research and development tax credits and unrestricted grants | 16 | 5 | 80 | 216 | ||
| Total other income (expense), net | [1] | 10,262 | (3,129) | (3,845) | (1,359) | |
| Net income (loss) before income taxes | 3,915 | (8,777) | (17,600) | (16,947) | ||
| Income tax expense | 0 | 0 | 0 | 0 | ||
| Net income (loss) | 3,915 | (8,777) | (17,600) | (16,947) | ||
| Other comprehensive income: | ||||||
| Foreign currency translation adjustments | 19 | 1 | 55 | 79 | ||
| Total other comprehensive income | 19 | 1 | 55 | 79 | ||
| Comprehensive income (loss) | $ 3,934 | $ (8,776) | $ (17,545) | $ (16,868) | ||
| Net income (loss) per share – basic and diluted | ||||||
| Basic (in dollars per share) | $ 0.3 | $ (0.85) | $ (1.42) | $ (1.77) | ||
| Diluted (in dollars per share) | $ 0.05 | $ (0.85) | $ (1.42) | $ (1.77) | ||
| Weighted average common shares used to compute basic and diluted net income (loss) per share | ||||||
| Basic (in shares) | 13,079,599 | 10,284,674 | 12,374,096 | 9,549,661 | ||
| Diluted (in shares) | 14,668,742 | 10,284,674 | 12,374,096 | 9,549,661 | ||
| Product [Member] | ||||||
| Revenue: | ||||||
| Total revenue | $ 43 | $ 0 | $ 118 | $ 65 | ||
| Royalty [Member] | ||||||
| Revenue: | ||||||
| Total revenue | $ 13 | $ 15 | $ 43 | $ 58 | ||
| ||||||
| X | ||||||||||
- Definition The amount of gain (loss) on issuance of equity. No definition available.
|
| X | ||||||||||
- Definition Amount of costs for issuance of common stock warrant liability. No definition available.
|
| X | ||||||||||
- Definition Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Total costs of sales and operating expenses for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of expense (income) related to adjustment to fair value of warrant liability. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in income from government assistance. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of interest expense classified as nonoperating. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount after tax of other comprehensive income (loss) attributable to parent entity. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|